BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2019 3:18:49 AM | Browse: 867 | Download: 960
 |
Received |
|
2018-10-09 10:07 |
|
Peer-Review Started |
|
2018-10-10 01:25 |
|
To Make the First Decision |
|
2018-11-29 07:49 |
|
Return for Revision |
|
2018-12-06 07:28 |
|
Revised |
|
2018-12-30 08:57 |
|
Second Decision |
|
2019-01-22 01:26 |
|
Accepted by Journal Editor-in-Chief |
|
2019-01-22 01:28 |
|
Accepted by Company Editor-in-Chief |
|
2019-01-23 16:00 |
|
Articles in Press |
|
2019-01-23 16:00 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-02-02 21:47 |
|
Typeset the Manuscript |
|
2019-02-25 10:20 |
|
Publish the Manuscript Online |
|
2019-02-26 03:18 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell Biology |
| Manuscript Type |
Review |
| Article Title |
Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qiang Liu, Mo-Xian Chen, Lin Sun, Chloe U Wallis, Jian-Song Zhou, Li-Juan Ao, Qi Li and Pak C Sham |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Nature Science Foundation of China |
81660381 |
|
| Corresponding Author |
Qi Li, PhD, Postdoctoral Fellow, Department of Psychiatry, the University of Hong Kong, 21 Sasson Roads, Pokfulam, Hong Kong , China. liqihku@gmail.com |
| Key Words |
Autism spectrum disorders; Mesenchymal stem cells; Major histocompatibility complex; Inflammation; Maternal immune activation; Cell therapy |
| Core Tip |
Autism spectrum disorder (ASD) is a complex, behaviorally defined disorder characterised by severe impairments in social communication and repetitive behavior. Because of an incomplete understanding of the pathology of ASD, available options of treatments in ASD are only symptomatic. We discuss the role of immune dysfunction in the etiology of ASD and function of mesenchymal stem cells (MSCs). We summerize the pre-clinical and clinical evidence for MSC therapy in ASD and suggest that more basic experiments are needed to better understanding of the therapeutic mechanisms of MSCs in ASD. |
| Publish Date |
2019-02-26 03:18 |
| Citation |
Liu Q, Chen MX, Sun L, Wallis CU, Zhou JS, Ao LJ, Li Q, Sham PC. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders. World J Stem Cells 2019; 11(2): 55-72 |
| URL |
https://www.wjgnet.com/1948-0210/full/v11/i2/55.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v11.i2.55 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
